Share LinkedIn Email Copy Link The companies’ late-stage stumble could allow Moderna to widen its lead, with its mRNA-based combination vaccine eliciting superior immune responses against COVID-19 and three influenza strains.Read more about this post on Biospace
EndPoints Pfizer ends work on Sangamo’s hemophilia gene therapy, crushing biotech’s hopesDecember 31, 2024
EndPoints Despite mixed data in Alzheimer’s agitation, Axsome will still seek FDA approvalDecember 30, 2024